Bhagirathbhai Dholaria, MD

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Travel
    Ineligible company:
    Janssen
    Date added:
    08/09/2023
    Date updated:
    04/04/2024
    Relationship end date:
    06/06/2023
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    ADC therapeutics
    Date added:
    08/09/2023
    Date updated:
    04/04/2024
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Arivan
    Date added:
    08/09/2023
    Date updated:
    04/04/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    MJH bio
    Date added:
    08/09/2023
    Date updated:
    04/04/2024
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Pfizer
    Date added:
    08/09/2023
    Date updated:
    04/04/2024
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    BMS
    Date added:
    08/09/2023
    Date updated:
    04/04/2024
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Gilead
    Date added:
    08/09/2023
    Date updated:
    04/04/2024
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Angiocrine
    Date added:
    08/09/2023
    Date updated:
    04/04/2024
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Wugen
    Date added:
    08/09/2023
    Date updated:
    04/04/2024
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Takeda
    Date added:
    08/09/2023
    Date updated:
    04/04/2024

Pages

Return to 2023 Annual Summit on Hematologic Cancers: Incorporation of Novel Therapies in Clinical Practice